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Background: Comorbidity has been noted as a potential barrier to proper adherence to antihypertensive medications.
Objectives: We decided to investigate whether comorbidity could significantly affect adherence of Iranian patients with hypertension to their medication regimen.
Patients and Methods: Two hundred and eighty consecutive hypertensive patients were interviewed in 4 cities of Iran. The 8-item Morisky medication adherence scale (MMAS-8) (validated in Persian) was used to assess medication adherence. This scale determines adherence by scores as lower than 6 (low adherence), 6 or 7 (moderate adherence), and 8 (high adherence). Comorbidity was considered as any concomitant medical condition, which necessitates the patient to take medicine for a minimum of 6 months prior to the interviews.
Results: The most common comorbid conditions were ischemic heart disease (65 patients, 23.2%), diabetes mellitus (55 patients, 19.6%), and dyslipidemia (51 patients, 18.2%). Mean (± SD) MMAS-8 score in comorbid group was 5.68 (± 1.85) and in non-comorbid hypertensive patients, it was 5.83 (± 1.91) (P = 0.631). Mean (± SD) number of comorbidities was 1.53 (± 0.75) in low adherence group compared to 1.54 (± 0.77) in moderate/high adherers (P = 0.98). With increasing the number of comorbid diseases, the proportion of patients with high adherence decreased successively from 20% in those with no comorbid disease to 14.1% in those with one or two comorbid conditions, and finally 11.1% in those with 3 to 5 comorbid conditions.
Conclusions: With increasing the number of comorbid conditions, the proportion of patients with high adherence decreases. In our opinion, this finding is a useful clinical note for healthcare providers when managing patients with hypertension who have other medical problems at the same time.
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Copyright © 2015, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. BackgroundUndoubtedly, one of the factors in controlling high blood pressure (BP) is good adherence to medication(s) prescribed. Adherence to (compliance with) the medica-tion has been described as active involvement of patients in taking medications prescribed to achieve an accept-able therapeutic result (1, 2). This is of so paramount clini-cal importance that even some experts believe that maxi-mizing adherence is more important in achieving good BP control compared to selecting a special drug class or regimen in the era of promising evidence of new classes of antihypertensives (3).In essence, medication adherence is a complex phenom-enon and discrete factors can influence on it. One of these contributing factors (which we think the relevant data about it are suboptimal) is the presence of a concomitant medical condition (i.e., comorbidity) (4). Previous perti-nent studies reported conflicting results. Some reported that adherence to antihypertensives decreases when co-
morbidity exists (5, 6). In other words, existence of multiple medical conditions has been viewed as a barrier to good medication adherence and prompts nonadherence. For instance, it was reported that medication adherence, mea-sured by medication possession ratio days’ supply of the drug dispensed in 1-year follow-up, was 80% in 72.3% of in-dividuals with hypertension (HTN) alone, which was better when compared to hypothyroidism comorbidity (68.4%) or gout comorbidity (36.8%) (7). Comorbidities are gener-ally addressed as barriers for patients with hypertension and putting them into consideration when assessing the patients’ adherence (3). In addition to physical illnesses, psychiatric conditions such as depressive symptoms have also been reported to adversely affect the adherence to an-tihypertensives (4) and cause poor BP control (8).In contrast, other authors found good adherence to antihypertensives in diabetic patients who were taking these drugs, a finding which was discovered in North 
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American countries (9-12). Another study from Scotland also did not find any relationship between the number of comorbidities and adherence (13).
2. ObjectivesConsidering the aforementioned facts, the scope of this study was to explore the hypothesis that whether non-comorbid patients with hypertension have better adher-ence to medication compared to comorbid patients and how presence of an additional medical condition, spe-cific disease, and the number of comorbidities affect the adherence of patients with high BP to the prescribed an-tihypertensive drugs. We believe that the findings of this study will be of splendid benefit for health care providers who deal with patients suffering from HTN and at least one concomitant medical condition in order to imple-ment the findings in attaining good BP control.
3. Patients and MethodsThis study with cross-sectional design method was con-ducted from August 2014 to December 2014. Sampling of the patients was done at several healthcare centers, including cardiology outpatient clinic of a university hospital, private cardiology, general practice offices, and pharmacy. These centers were located in Tehran, Karaj, Kermanshah, and Bafgh. Inclusion criteria consisted of patients aged more than 18 years with HTN under treat-ment. The interviews with the patients were done face to face by the research team members.To determine the adherence to antihypertensives, the Persian version of the MMAS-8 (the 8-item Morisky Medi-cation Adherence Scale) (validated by our team in a previ-ous study) was administered to the patients. The MMAS-8 was designed to assess how well the patients adhere to their medications (Appendix 1) (14). As shown in Appen-dix 1, it has 8 questions. For questions 1 to 7, the answer options are “yes” or “no”. The eighth question is a Likert-type question. The overall score of this scale is from 0 to 8. The categorization of patients considering their score is as follows: less than 6 (low adherence), 6 or 7 (moderate adherence), and 8 (high adherence). This scale showed a sensitivity of 93% in finding those individuals with poor adherence (15). It was also demonstrated to be signifi-cantly associated with antihypertensive drug pharmacy refill adherence (16). In our previous study on 200 Iranian patients suffering from HTN, we determined the Persian version of the MMAS-8 to be a valid and reliable tool with the Cronbach α coefficient of 0.697 and test–retest reli-ability of 0.940 (17).Besides MMAS-8, we employed a data-gathering form to collect demographic information as well as variables about other diseases or medications the patients report-ed or took at the time of study. Comorbidity was con-sidered as any concomitant medical condition, which necessitates the patient to take medicine for at least 6 months before the interview time to control symptoms and signs of the disease or impaired laboratory data (e.g., 
blood glucose, lipid profile, thyroid function tests). Other medical condition(s) could be secondary to HTN or unre-lated to that. Chronic Kidney Disease (CKD) was defined in patients with documents (laboratory, nephrologist, or discharge reports) of impaired renal function and decreased glomerular filtration rate (GFR) so severe that patients had to receive medications (e.g., for anemia) and or were receiving hemodialysis (18).First, the MMAS was completed by the patients. After completing it, the checklist data was completed. The vari-ables of the checklist consisted of demographic data (age, gender, weight, height, occupation, educational level), HTN duration, medications prescribed for HTN, other co-morbidities, medications other than antihypertensives, and control of hypertension during the last 6 months by a healthcare provider. At the end, BP of the patients was measured. For this purpose, sphygmomanometer was used to measure BP on the left arm in sitting position. The patients were asked to sit relaxed and not to smoke for half an hour before BP measurement.
3.1. Statistical AnalysesDescriptive indexes, including frequency, percentage, mean, and standard deviation were used to express data. Adherence level was compared between the groups with the Chi-square test. The MMAS-8 scores were compared between groups by the Mann-Whitney U test. All analyses were done by the SPSS software for Windows (ver. 16.0). Significance level was set at 0.05.
3.2. EthicsAfter describing the purpose of the study and gather-ing information, verbal consent was obtained from the patients.
4. ResultsMean (± SD) age of the participants was 60.3 (± 10.0) years. Mean (± SD) duration of HTN was 7.2 (± 5.9) years (range, 6 months to 40 years). Table 1 summarizes demo-graphic characteristics of the sample.General practitioners (67 patients, 23.9%) and cardiolo-gists (65 patients, 23.2%) were the most reported physi-cians whom the patients visited to control their high BP. Others reported visiting internists (24 patients, 8.6%), ne-phrologists (9 patients, 3.2%), or more than one physician to check their BP (115 patients, 41.0%).Nearly half of the patients (127 patients, 45.3%) were tak-ing one class of antihypertensive medication for their condition. Over one-fourth of the patients, 74 (26.4%) were prescribed angiotensin receptor blockers, the most prevalent medication used.Mean (± SD) overall MMAS-8 score was 5.75 (± 1.88). About half of the sample (139 patients, 49.6%) showed low ad-herence to antihypertensives. Ninety-five patients (33.9%) had moderate adherence and 46 patients (16.4%) showed high adherence level.
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Table 1.  Demographic Characteristics of 280 Patients with Hypertension 
Demographic Characteristics Frequency (%)
GenderMale 118 (42.1)Female 162 (57.9)
Age, y≤ 50 51 (18.2)> 50 229 (81.8)
BMI, kg/m2< 25 76 (27.1)≥ 25 204 (72.9)
EducationLower than high school diploma/illiterate 164 (58.5)High school diploma 71 (25.4)Academic degree 45 (16.1)
OccupationMarket trader/self-employed 73 (26.1)Clerk/military 41 (14.6)Housewife 119 (42.5)Retired/unemployed 47 (16.8)
Current smoker 49 (17.5)
Insurance coverage 246 (87.8)
Residence placeUrban 273 (97.5)Rural 7 (2.5)
Of 280 patients, 160 patients (57.1%) had at least one co-morbid condition. However, 120 patients (42.9%) did not have any comorbidity. Ninety-six patients (34.2%) had one comorbid disease, 46 patients (16.4%) had 2 comorbid dis-eases, and 18 patients (6.4%) had 3 diseases or more with HTN. The most common comorbid condition was isch-emic heart disease (65 patients, 23.2%) with or without history of coronary artery bypass grafting or percutane-ous coronary intervention, followed by diabetes melli-tus (55 patients, 19.6%), dyslipidemia (51 patients, 18.2%), psychiatric conditions (8 patients, 2.8%), CKD (7 patients, 2.5%), as well as gout and hypothyroidism (each was seen in 6 patients, 2.1%). Other conditions (congestive heart failure, osteoporosis, chronic obstructive pulmonary disease, malignancies, chronic low back pain, anemia, benign prostatic hyperplasia, osteoarthritis, and so on) had frequencies of 5 patients or fewer.Mean (± SD) MMAS-8 score in comorbid group was 5.68 (± 1.85) and in non-comorbid hypertensives was 5.83 (± 1.91) (P = 0.631). Table 2 presents the comparison of adher-ence levels (low vs. moderate/high adherence) in terms of comorbidity and its mean number. As shown, no signifi-cant difference was detected between low adheres and moderate/good adherers regarding these two variables.In Table 3, comparison of 3 most common comorbid conditions between low adherers and moderate/high adherers is depicted. Similar to Table 2, no significant difference was observed regarding these 3 comorbid conditions between low and moderate/high adherence levels.
Table 2.  Comparison of Adherence Level (low vs. moderate/high adherence) in Terms of Comorbidity and Its Mean Number a
Low Adherence (MMAS-8 
score < 6)
Moderate/High Adherence 
(MMAS-8 score = 6 - 8)
P Value
Comorbidity 0.62Yes 77 (48.1%) 83 (51.9%)No 62 (51.7%) 58 (48.3%)
Number of comorbidities, mean ± SD 1.53 ± 0.75 1.54 ± 0.77 0.98a  Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA Fielding School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA.
Table 3.  Anti-Hypertensive Adherence Level Status Considering the 3 Most Common Comorbid Conditions Reported in the Sample of 280 Patients With Hypertension a,b
Low Adherence (MMAS-8 
Score < 6), N. (%)
Moderate/High Adherence 
(MMAS-8 score = 6 - 8), N. (%)
P Value
IHD ± CABG/PCI a,b 0.48Yes 35 (53.8) 30 (46.2)No 104 (48.4) 111 (51.6)
Dyslipidemia 0.87Yes 26 (51) 25 (49)No 113 (49.3) 115 (50.7)
DM 0.22Yes 23 (41.8) 32 (58.2)No 116 (51.6) 109 (48.4)a  Abbreviations: CABG, Coronary artery bypass grafting; DM, Diabetes mellitus; PCI, Percutaneous coronary intervention.b  Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA Fielding School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA.
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Of 7 patients with CKD, 3 patients had only CKD; 1 pa-tient had CKD and IHD. One patient had CKD and gout. Two patients had DM and IHD in addition to CKD. Mean (SD) MMAS-8 score in this group was 6.21 (1.72); range 3 - 8. Two patients (one with CKD and another with CKD plus gout) had good adherence (i.e., score of 8). One patient with just CKD had poor adherence (score of 3). Others had moderate adherence level. Figure 1 depicts adherence level (low, moderate, and high) with respect to the number of comorbidities. As seen, with increasing the number of comorbid condi-tions, the proportion of high adherers decreased. In fact, high level of adherence (i.e., MMAS-8 score = 8) was cal-culated in patients without comorbidity as 20.0%. It was 14.1% for those with one or two comorbid conditions, and 11.1% for those with 3 - 5 comorbid conditions.
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Figure 1. Antihypertensive Adherence Level (Low, Moderate, and High) and Number of Comorbid Conditions
5. DiscussionAdherence studies in Iran are extremely insufficient. There are few relevant studies targeting patients with HTN, however their design, quality, and methods used to define adherence are questionable (19). We did not find any previous study to address patient and practice-relat-ed as well as adherence report in Iranian hypertensive patients with multiple medical conditions. Adherence studies in such patients can be even more important con-sidering the fact that cardiovascular events increase sev-eral times when a hypertensive patient has concomitant conditions such as diabetes or dyslipidemia (6).According to the obtained findings, comorbidities that necessitated regular medication consumption did not affect the patients’ compliance with antihypertensive. Neither the number of comorbidities, nor their specific types (IHD, DM, and dyslipidemia) were found to adverse-ly affect the adherence level. The presence of comorbid-ity and its influence on adherence can be viewed from 2 aspects. One is related to the nature of the comorbidity itself and the other relates to the medication taken by the patient for the comorbidity. The clinicians should not ignore the second view. For example, concomitant use 
of antihypertensive and lipid-lowering therapy was as-sociated with poor adherence and about 45% were dem-onstrated to be adherent; the figure declined to 36% at 1-year follow-up (20). As mentioned earlier, the results of former studies about the role of comorbidity are heterogeneous. This may be related to the fact that ad-herence to medication is a complex phenomenon and various factors, including knowledge and attitude of patients towards HTN, health care system issues, doc-tor-patient relationship,  and the role of pharmacists all have significant impact on adherence and its improve-ment (5, 21-23).In an American study (6) to evaluate adherence in hy-pertensive patients with DM (using proportional days covered (PDC) for both oral DM and HTN medications), the authors reported that preexisting disease, older age, higher number of medications, and doctor-related vari-ables (e.g., prescription for both DM and HTN medica-tions provided by a single doctor) were significant fac-tors in determining multiple medication adherence. In contrast, Chapman et al. found that taking fewer medications was a factor associated with better adher-ence in patients taking medications for HTN and dyslip-idemia (20). In another study conducted on more than 700,000 patients, using mean medication possession ratio to determine adherence, it was shown that adher-ence decreased with the presence of any of the 6 comor-bid conditions, including hypothyroidism, type 2 DM, seizure disorders, hypercholesterolemia, osteoporosis, and gout (7).
5.1. Strengths and limitationsGiven that the presented data were collected from dif-ferent settings, including outpatient cardiology clinic of university hospital, private cardiology and general prac-tice offices, and pharmacy at different parts of Iran, the sample may be a good representative of Iranian popula-tion and the results have good generalizability. Further-more, we employed the MMAS-8 to define antihyperten-sive adherence. The MMAS-8 has been reported in several studies across different cultures and languages as a reli-able tool in determining adherence level of patients with HTN (24, 25). As mentioned above, we also observed a good reliability and validity of this scale in Persian speak-ing patients in a previous study (17).On the other hand, as a broad range of factors can affect medication adherence, we were not able to study all pos-sible related factors such as patient education, psycho-logical factors, attitude and knowledge of the patients, and the like. Also, access to medical records of all patients was not feasible as some were interviewed at pharmacies and some patients were interviewed when they present-ed to the clinic for the first time and we relied solely on subjective information provided by the patients. There-fore, recall bias might be a concern. However, this was not true in all subjects.
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5.2. Suggestions for Future ResearchersIt would be a good idea to design a questionnaire to in-clude physical, psychological, therapeutic, and social fac-tors related to healthcare management, and economic issues of the patients who are suffering from another co-morbid disease besides HTN when studying medication adherence. As stated earlier, medication adherence is a complex phenomenon and both patient-related factors as well as healthcare system-related factors are involved in it. Studying other important factors, such as medica-tion cost, differences between generic and brand forms of a single medication, visual acuity of patients and the role of the pharmacists seem necessary for better under-standing of adherence in Iran. This will be of outmost benefit to have the opportunity for more complex analy-ses to find factors with significant association with medi-cation adherence.Although with increasing the number of comorbid conditions, the proportion of patients with high adher-ence decreases, neither the presence nor the number of comorbid diseases showed statistically significant as-sociation with antihypertensive adherence in comorbid hypertensive patients. With individual analysis, neither IHD, nor DM, and nor dyslipidemia showed significant association with antihypertensive adherence.
Appendix 1. The 8-Item Morisky Medication Adherence Scale (MMAS-8)Item 1. Do you sometimes forget to take your antihyper-tensive pills?Item 2. People sometimes miss taking their medications for reasons other than forgetting. Thinking over the past 2 weeks, were there any days when you did not take your antihypertensive medicine?Item 3. Have you ever cut back or stopped taking your medication without telling your doctor, because you felt worse when you took it?Item 4. When you travel or leave home, do you some-times forget to bring along your antihypertensive medi-cation?Item 5. Did you take your antihypertensive medicine yesterday?Item 6. When you feel like your antihypertensive is un-der control, do you sometimes stop taking your medi-cine?Item 7. Taking medication every day is a real inconve-nience for some people. Do you ever feel hassled about sticking to your antihypertensive treatment plan?Item 8. How often do you have difficulty remembering to take all your medications?Never, rarely, sometimes, usually, or all the time.
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